Sybleu Inc. Secures Exclusive License for AI/ML Small Molecule Drug Design Engine

Image Source : Public Domain

Because Sybleu has developed a corporate strategy centered around acquiring intellectual property and forging strategic partnerships to advance technologies to market, the company has been carefully screening potential in-licensing opportunities as it builds its portfolio.

The company has identified a technology owned by DYO Biotechnologies, Pty, Ltd which is centered around artificial intelligence and machine learning and that has already been used to create a drug currently in clinical trials. 

Specifically, this technology consists of an artificial intelligence/machine learning engine designed to utilize existing chemical library structures in an integrated model to predict highly specific and sensitive novel chemical structures for molecular targets.  Any future small molecule drugs that Sybleu in-licenses or develops can be rapidly improved and moved forward in the development process using this intellectual property.

Under the terms of the license agreement, Sybleu will have exclusive, worldwide rights to the intellectual property and will own any intellectual property that DYO will be contracted to develop.  Furthermore, Sybleu will have the right to sublicense the technology.

"As the company puts together the building blocks for an exciting future, we want to stay focused on using the latest cutting-edge technologies to get our products to market in an efficient and rapid manner," said Joseph Vaini, CEO of Sybleu.  "Utilizing this advanced AI/ML technology can be of great benefit to our future small molecule programs and, potentially, to other companies developing small molecules."